Bitcoin groundbreakers share personal stories of how Bitcoin is changing lives for the better. Host Mauricio Di Bartolomeo, co-founder and CSO of Ledn, speaks with leading Bitcoin voices, entrepreneurs, and human rights advocates to hear their unique journey and practical real-world examples of how Bitcoin has made a positive impact in their lives. Brought to you by Ledn, a leading financial services company built for Bitcoin & digital assets. Ledn offers a suite of lending, saving and tradi ...
…
continue reading
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Player FM -播客应用
使用Player FM应用程序离线!
使用Player FM应用程序离线!
Tryptamine Therapeutics Begins Phase 2a Trial for IBS Treatment at MGH
Manage episode 430778395 series 2891889
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Tryptamine Therapeutics Ltd (ASX: TYP) president and chief scientific officer Jim Gilligan joins Jonathan Jackson in the Proactive studio to discuss the company’s Phase 2a clinical trial at Massachusetts General Hospital (MGH) in the US, targeting the treatment of Irritable Bowel Syndrome (IBS). The trial involves administering oral psilocybin, known as TRP-8802, combined with psychotherapy. MGH, part of the Mass General Brigham health system and Harvard's oldest hospital, is participating in this study for the first time. Up to ten patients will receive the treatment, with primary efficacy endpoints focused on reducing chronic abdominal pain and visceral tenderness. Results are anticipated in the first quarter of 2025. This trial will guide further research on TRP-8803, an IV-infused psilocin, expected to offer improved efficacy, safety, faster onset, precise control, and reduced intervention duration compared to oral psilocybin. IBS affects up to 20% of Australians and 15% of the US population and represents a significant unmet medical need, impacting productivity and quality of life. Tryptamine Therapeutics aims to address this need by exploring the gut-brain relationship through their ongoing and future clinical trials. Gilligan highlighted the collaboration with MGH, noting its prestigious reputation and significant interest in psychedelic compounds for treating unmet medical needs. Tryptamine Therapeutics is also advancing clinical trials for other conditions, including binge eating disorder and fibromyalgia. #ProactiveInvestors #ASX #TryptamineTherapeutics #IBS #ClinicalTrial #Psilocybin #TRP8802 #MassGeneralHospital #MGH #Harvard #GutBrainRelationship #Psychotherapy #TRP8803 #PsychedelicResearch #UnmetMedicalNeed #Productivity #QualityOfLife #Biotech #HealthcareInnovation #MentalHealth #BingeEatingDisorder #Fibromyalgia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
621集单集
Manage episode 430778395 series 2891889
内容由Proactive Investors提供。所有播客内容(包括剧集、图形和播客描述)均由 Proactive Investors 或其播客平台合作伙伴直接上传和提供。如果您认为有人在未经您许可的情况下使用您的受版权保护的作品,您可以按照此处概述的流程进行操作https://zh.player.fm/legal。
Tryptamine Therapeutics Ltd (ASX: TYP) president and chief scientific officer Jim Gilligan joins Jonathan Jackson in the Proactive studio to discuss the company’s Phase 2a clinical trial at Massachusetts General Hospital (MGH) in the US, targeting the treatment of Irritable Bowel Syndrome (IBS). The trial involves administering oral psilocybin, known as TRP-8802, combined with psychotherapy. MGH, part of the Mass General Brigham health system and Harvard's oldest hospital, is participating in this study for the first time. Up to ten patients will receive the treatment, with primary efficacy endpoints focused on reducing chronic abdominal pain and visceral tenderness. Results are anticipated in the first quarter of 2025. This trial will guide further research on TRP-8803, an IV-infused psilocin, expected to offer improved efficacy, safety, faster onset, precise control, and reduced intervention duration compared to oral psilocybin. IBS affects up to 20% of Australians and 15% of the US population and represents a significant unmet medical need, impacting productivity and quality of life. Tryptamine Therapeutics aims to address this need by exploring the gut-brain relationship through their ongoing and future clinical trials. Gilligan highlighted the collaboration with MGH, noting its prestigious reputation and significant interest in psychedelic compounds for treating unmet medical needs. Tryptamine Therapeutics is also advancing clinical trials for other conditions, including binge eating disorder and fibromyalgia. #ProactiveInvestors #ASX #TryptamineTherapeutics #IBS #ClinicalTrial #Psilocybin #TRP8802 #MassGeneralHospital #MGH #Harvard #GutBrainRelationship #Psychotherapy #TRP8803 #PsychedelicResearch #UnmetMedicalNeed #Productivity #QualityOfLife #Biotech #HealthcareInnovation #MentalHealth #BingeEatingDisorder #Fibromyalgia #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews
…
continue reading
621集单集
All episodes
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。